SHO-SAIKO-TO for Patients With Chronic Hepatitis C: A Phase II Study
Study Details
Study Description
Brief Summary
Researchers want to see whether Sho-saiko-to (SST) can help in patients with chronic hepatitis C. Chronic hepatitis C may cause swelling within the liver and this can lead to scar tissue. In some patients, severe scarring of the liver, liver failure and liver cancer can occur. Standard treatment for chronic hepatitis C is a drug called interferon with or without another drug called ribavirin. There are a number of side effects that some patients are unable to take. Other patients may have an initial response, but then the virus and the inflammation come back.
Sho-saiko-to is an herbal medicine that has been used for many years in Asia to treat liver disease. The purpose of the study is to evaluate whether Sho-saiko-to may improve liver swelling and injury caused by chronic hepatitis C.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Detailed Description
Chronic hepatitis C affects nearly three million Americans. Of these, 15% will develop liver cirrhosis and approximately 5% will progress to hepatocellular carcinoma. Treatment for chronic hepatitis C is limited to interferon-based therapy. Many patients decline or cannot tolerate interferon because of its serious side effects. Sho-saiko-to, an Asian herbal medicine consisting of seven botanicals, has demonstrated anti-fibrotic affect by inhibition of lipid peroxidation in hepatocytes and stellate cells in an animal study. It has also been demonstrated to prevent progression of cirrhosis to hepatocellular carcinoma in human trials. This study is a single arm, single center trial of Sho-saiko-to in patients with chronic active hepatitis from hepatitis C infection who cannot tolerate or who have specific contraindications to interferon therapy. Patients will receive 52 weeks therapy with Sho-saiko-to. Outcome will be assessed by comparing pre- and posttreatment liver biopsies. Patients will be said to respond if they have an improvement of two points or greater on a standard measure of liver histology. If five or more of 25 evaluable patients respond, Sho-saiko-to will be deemed worthy of further testing.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: 1 All patients will receive treatment with 2.5grams of SST as granules in packet form by mouth three times a day every day for 52 weeks unless occurrence of unacceptable adverse events or patient withdrawal. |
Drug: Sho-saiko-to
All patients will receive treatment with 2.5grams of SST as granules in packet form by mouth three times a day every day for 52 weeks unless occurrence of unacceptable adverse events or patient withdrawal. Patients will be seen for clinical follow-up at three month intervals: at 3, 6, 9, and 12 months, and assessed for compliance and asked about side effects and pulmonary symptoms. At each clinic visit, a comprehensive metabolic profile will be performed. At the 6-month clinic visit, a CBC will be performed. At the 12-month clinic visit, quantitative HCV-RNA by PCR will be obtained (Viromed Labs, Inc., 6101 Blue Circle Drive, Minneapolis, MN 5534). Within 4 weeks after the 12-month clinic visit (after 52 weeks of SST therapy), the second liver biopsy will be scheduled and performed.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- To Determine the Effects of Sho-saiko-to on Hepatic Injury in Patients With Chronic Hepatitis C Who Are Intolerant or Have a Specific Contraindication to Interferon-based Therapy. [52 weeks]
Response is determined by improvement of 2 points or greater as per Knodell's histology activity index (HAI) scores in paired comparisons of pre and post liver biopsy
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Chronic hepatitis C diagnosis, with abnormal liver function tests, positive serology for Hepatitis C antibody, positive viremia as indicated by PCR techniques.
-
Age 18 or over
-
There must be no plans to use interferon in the following 12 months due to EITHER: a specific contraindication to interferon therapy, including but not limited to:history of depression, or other psychiatric disease, history of autoimmune disease,psoriasis, rheumatoid arthritis, history of renal dysfunction, thyroid abnormalities, seizure disorder, depressed blood cell counts, history of asthma OR patient discontinuation of interferon-based therapy prematurely due to intolerable side effects with sustained active viremia OR patient refusal to take interferon
-
Patients must be able to understand and sign informed consent.
-
Female participants must agree to practice approved methods of birth control (if applicable).
Exclusion Criteria:
-
Coinfection with hepatitis B as defined by a positive Hepatitis B surface antigen (HBsAg) test.
-
Coinfection with HIV
-
Patients with alcohol intake >40g day
-
Patients with recent myocardial infarction or heart failure.
-
Concurrent use of Sho-saiko-to, or any of its constituent plants.
-
Concurrent use of interferon containing products.
-
Use of interferon-based treatment within the past 6 months.
-
Women who are pregnant, nursing, or have the potential to becoming pregnant, unless utilizing birth control. A negative pregnancy test must be documented during the screening period for women of childbearing potential.
-
History of malignancy, unless there is currently no evidence of disease and patient completed all surgery, radiotherapy and chemotherapy for that disease a minimum of two years previously
-
Concurrent life-threatening illness, for which the prognosis is poor.
-
Patients with diffusing capacity on pulmonary testing less than 50% of predicted will be excluded.
-
Patients with diffusing capacity on pulmonary testing less than 70% of predicted AND total lung capacity less than 80% of predicted will be excluded.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Memorial Sloan Kettering Cancer Center | New York | New York | United States | 10065 |
Sponsors and Collaborators
- Memorial Sloan Kettering Cancer Center
Investigators
- Principal Investigator: Gary Deng, MD, PhD, Memorial Sloan Kettering Cancer Center
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- 02-073
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | All Patients |
|---|---|
| Arm/Group Description | Sho-saiko-to: All patients will receive treatment with 2.5grams of SST as granules in packet form by mouth three times a day every day for 52 weeks. |
| Period Title: Overall Study | |
| STARTED | 42 |
| COMPLETED | 24 |
| NOT COMPLETED | 18 |
Baseline Characteristics
| Arm/Group Title | All Patients |
|---|---|
| Arm/Group Description | Sho-saiko-to: All patients will receive treatment with 2.5grams of SST as granules in packet form by mouth three times a day every day for 52 weeks. |
| Overall Participants | 42 |
| Age (Count of Participants) | |
| <=18 years |
0
0%
|
| Between 18 and 65 years |
40
95.2%
|
| >=65 years |
2
4.8%
|
| Sex: Female, Male (Count of Participants) | |
| Female |
13
31%
|
| Male |
29
69%
|
Outcome Measures
| Title | To Determine the Effects of Sho-saiko-to on Hepatic Injury in Patients With Chronic Hepatitis C Who Are Intolerant or Have a Specific Contraindication to Interferon-based Therapy. |
|---|---|
| Description | Response is determined by improvement of 2 points or greater as per Knodell's histology activity index (HAI) scores in paired comparisons of pre and post liver biopsy |
| Time Frame | 52 weeks |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | All Patients |
|---|---|
| Arm/Group Description | Sho-saiko-to: All patients will receive treatment with 2.5grams of SST as granules in packet form by mouth three times a day every day for 52 weeks. |
| Measure Participants | 24 |
| Responders |
5
11.9%
|
| Non-responders |
19
45.2%
|
Adverse Events
| Time Frame | ||
|---|---|---|
| Adverse Event Reporting Description | ||
| Arm/Group Title | All Patients | |
| Arm/Group Description | Sho-saiko-to: All patients will receive treatment with 2.5grams of SST as granules in packet form by mouth three times a day every day for 52 weeks. | |
All Cause Mortality |
||
| All Patients | ||
| Affected / at Risk (%) | # Events | |
| Total | / (NaN) | |
Serious Adverse Events |
||
| All Patients | ||
| Affected / at Risk (%) | # Events | |
| Total | 3/24 (12.5%) | |
| Cardiac disorders | ||
| Conduction abnormality | 1/24 (4.2%) | 1 |
| Reproductive system and breast disorders | ||
| Pneumonia | 1/24 (4.2%) | 1 |
| Skin and subcutaneous tissue disorders | ||
| Cellulitis (skin) | 1/24 (4.2%) | 1 |
Other (Not Including Serious) Adverse Events |
||
| All Patients | ||
| Affected / at Risk (%) | # Events | |
| Total | 14/24 (58.3%) | |
| Blood and lymphatic system disorders | ||
| Neutrophils | 3/24 (12.5%) | 3 |
| Aspartate Aminotransferase (AST) | 6/24 (25%) | 6 |
| Alanine Aminotransferase (ALT) | 11/24 (45.8%) | 11 |
| Gastrointestinal disorders | ||
| Abdominal pain/cramping | 2/24 (8.3%) | 2 |
| Hepatobiliary disorders | ||
| Bilirubin | 2/24 (8.3%) | 2 |
| Metabolism and nutrition disorders | ||
| Hyperglycemia | 4/24 (16.7%) | 4 |
| Hypoalbuminemia | 2/24 (8.3%) | 2 |
Limitations/Caveats
More Information
Certain Agreements
All Principal Investigators ARE employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Dr. Gary Deng |
|---|---|
| Organization | Memorial Sloan Kettering Cancer Center |
| Phone | 646-888-0841 |
| dengg@mskcc.org |
- 02-073